AGTC to Host First Quarter Financial Results Conference Call and Webcast on November 9, 2021
Applied Genetic Technologies Corporation (Nasdaq: AGTC) will report its financial results for the quarter ending September 30, 2021, on November 9, 2021, before the market opens. A conference call hosted by AGTC management will commence at 8:00 AM ET to discuss the financial outcomes and provide a corporate update.
AGTC specializes in gene therapies for rare retinal diseases. The company is advancing clinical trials for conditions like X-linked retinitis pigmentosa and achromatopsia, leveraging its technology platform to enhance patient outcomes.
- AGTC is conducting human clinical trials for rare inherited retinal diseases, potentially addressing substantial unmet clinical needs.
- The company has strategic partnerships with Otonomy, Inc. and Bionic Sight, enhancing its development capabilities in neurotology and optogenetics.
- None.
GAINESVILLE, Fla., and CAMBRIDGE, Mass., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases, today announced that it will report financial results for the quarter ended September 30, 2021 before the market opens on Tuesday, November 9, 2021. AGTC management will host a conference call beginning at 8:00 AM Eastern Time on the same day to review the financial results and provide a corporate update.
To access the call, dial 877-407-6184 (US) or 201-389-0877 (outside of the US). A live webcast will be available in the Events and Presentations section of the Investor Relations page at http://ir.agtc.com/events-and-presentations. Please log in approximately 10 minutes prior to the scheduled start time. The archived webcast will be available in the Events and Presentations section of the company's website.
About AGTC
AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies with the potential to address real patient needs. AGTC’s most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with an inherited retinal disease. AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 and ACHM CNGA3). Its preclinical programs build on the Company’s industry leading AAV manufacturing technology and scientific expertise. AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders, including entering into strategic partnerships with companies including Otonomy, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, and Bionic Sight, LLC, an innovator in the emerging field of optogenetics and retinal coding.
IR Contact:
David Carey
Lazar FINN Partners
T: (212) 867-1768
david.carey@finnpartners.com
Corporate Contact:
Jon Lieber
Chief Financial Officer
Applied Genetic Technologies Corporation
T: (617) 843-5778
jlieber@agtc.com
FAQ
When will AGTC report its financial results for Q3 2021?
What time is AGTC's conference call to discuss financial results?
What clinical trials is AGTC currently conducting?
What is the focus of AGTC's clinical programs?
